Evan Lipson
@evanlipson
Oncologist and immunotherapy researcher focused on advanced skin cancer.
ID: 60559864
http://www.HopkinsMelanoma.org 27-07-2009 10:37:08
514 Tweet
1,1K Followers
519 Following
Great to be back at the Melanoma Research scientific retreat with friends from around the world including Jason Luke, MD, FACP
Sine 2013, my Johns Hopkins Medicine team and I have led development of a new #Immunotherapy, which was approved today by FDA for advanced #Melanoma onclive.com/view/fda-appro… via @onclive
Oncology milestone in #melanoma w U.S. FDA approval of anti-LAG3 relatlimab. The 3rd checkpoint! Congrats Hussein Tawbi, MD, PhD Evan Lipson Steve Hodi & Professor Georgina Long AO bringing this forward. Triplet IO w CTLA4 in mel vs PD1+LAG3 +TKI/chemo & for other cancers? onclive.com/view/fda-appro…
Congratulations to Dr. Kara Schenk for earning received a 2022 Conquer Cancer, the ASCO Foundation – Endowed Merit Award in honor of Dr. Cecil "Pete" Coggins. Dr. Schenk received this award for earning the highest score for her abstract focused on melanoma. We're so proud of you, Dr. Schenk!
Wonderful to see #KaraSchenk & Evan Lipson’s trial on the use ICIs in patients with renal transplants and cancer! So exciting! Results with nivo/ipi markedly improved from single agent nivo! More to come! NCI CTEP Clinical Research National Cancer Institute NCI Treatment HopkinsHemOncFellowship Johns Hopkins Kimmel Cancer Center
Great to be at #ASCO2022 & reviewing data for #melanoma pts: short-course braf+mek does not appear to enhance pd1 activity on neoadjuvant platform (Melanoma Institute Australia NeoTrio trial); pembrolizumab decreases the risk of DMFS c/f placebo (Keynote 716); pathCR rate 55% desmoplastic mel.
.Dawn Flythe Moore, Jamie, Mia, and I loved having the Easter Bunny here at Government House for this year’s annual Easter Egg Roll, but Tucker was the most excited of all! 🐶🐰
Our trial investigated how immunotherapy can help organ #transplant recipients fight #skincancer and keep their transplanted organs safe. Elad Sharon @headneckmd ascopubs.org/doi/10.1200/JC…
The Society for Immunotherapy of Cancer NMSC CPG rapid update v1.1 includes new/revised clinical recommendations pertaining to additional anti-PD-1 therapies for patients with CSCC and MCC. More information: sitcancer.org/NMSC-guideline #SITCGuidelines #NMSC #CSCC #MCC #Immunotherapy